In this part of his Pharmaceutical Executive video interview,Jonathan Scheinberg, of the Northeast Science and Technology Center, talks about strategies companies can adopt to attract and retain top talent in these competitive mega campus locations.
Well, it starts off with being in the right location. There are a number of markets in the country that you know have the human capital, you know, portion of the equation, the talent pool that you can attract, or you can actually hire from. And you know that starts with, you know, good school system, good quality of life, being proximate to medical and educational institutions. And you know, that's the talent pool that these companies need to draw from.
So, you see, these companies tend to focus on clusters like Boston, New York, New You know, northern jersey, Philadelphia, San Francisco, San Diego, and some other markets like the 270 quarter in Maryland and the research triangle in North Carolina. These markets have commonality in the sense that they have large medical and educational institutions that are training these people to actually be able to do the science or work for these companies. And without that, you can't build a talent base or an employee base. I should say, what's happened over the past? I'd say five or seven years is a little bit different than what's what was historic in the pharmaceutical industry, a lot of the scientists were thrown, at least perception wise, into the basement. In the dark corners of the of the building to do research. I think a lot of companies realize that these people are people like everybody else, and they're amazing people, and they want space looking at, you know, outside of a window. They want light and air. They want access to, sunny views and things like that, just like everybody else.
So, in lab design, I think it's been changing over the past couple of years that we're putting labs more on the perimeter of the building, rather than the core of the building, and addressing people's, you know, needs for sunshine and light, especially in the winter. So, no one gets seasonal affective disorder, but no. So that's actually a big shift. I would say, creating that that positive, you know, collaborative, innovative feeling for at least the employees.
IMF Chief Medical Officer Discusses Global Initiatives to Improve Myeloma Treatment
August 20th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.
AbbVie Presents New Data from Antibody-Drug Conjugates Across Multiple Indications at ASCO 2024
June 13th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Pedro Valencia, VP, Solid Tumor Pipeline Strategy & Execution, AbbVie, discusses data presented at ASCO from ABBV-400 and ABBV-706 in multiple studies.
Planning for Unique Challenges Faced by Cell & Gene Therapy Developers
May 8th 2024In an interview with Pharm Exec Associate Editor Don Tracy, Melissa Lattanzi, VP, Emerging Therapies, Cencora, discusses the unique challenges that developers of cell and gene therapies need to plan for when building their channel strategy.
Pricing Climate Impacting Commercial Considerations
May 3rd 2024In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.